Anthony Rowan, Tiarnan Fallon Verbruggen, Nuala H. O'Connell, Patrick J. Stapleton, Colum P. Dunne, Barry Linnane, Daryl Butler
{"title":"Indwelling central venous catheter infection with Chryseobacterium shandongense – successful eradication in a 5-year-old with cystic fibrosis","authors":"Anthony Rowan, Tiarnan Fallon Verbruggen, Nuala H. O'Connell, Patrick J. Stapleton, Colum P. Dunne, Barry Linnane, Daryl Butler","doi":"10.1099/acmi.0.000700.v3","DOIUrl":null,"url":null,"abstract":"\n Introduction.\n \n \n Chryseobacterium shandongense\n \n is a Gram-negative \n \n Flavobacterium\n \n bacillus with intrinsic multidrug-resistant properties.\n \n Case Presentation. Herein, we present the first case report of human \n \n C. shandongense\n \n infection, relating to an implantable portal and catheter (port-a-cath) central line in a 5-year-old female with cystic fibrosis. The infection was identified using a Bruker MALDI-TOF Biotyper with BDAL (v12) of blood, which was cultured due to pyrexia and rigour following port-a-cath access. This report details the effective eradication of \n \n C. shandongense\n \n infection from the port-a-cath device using initial empirical gentamicin followed by targeted ciprofloxacin locks and systemic antibiotics.\n \n Conclusion. We demonstrated successful eradication of \n \n C. shandongense\n \n from a port-a-cath device, including the minimum inhibitory concentrations (MICs) required in this case. The result was eradication of central access infection, preventing progression to bacteraemia/septicaemia and preserving central access in a child with cystic fibrosis and established respiratory disease.","PeriodicalId":6956,"journal":{"name":"Access Microbiology","volume":"114 15","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Access Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1099/acmi.0.000700.v3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction.
Chryseobacterium shandongense
is a Gram-negative
Flavobacterium
bacillus with intrinsic multidrug-resistant properties.
Case Presentation. Herein, we present the first case report of human
C. shandongense
infection, relating to an implantable portal and catheter (port-a-cath) central line in a 5-year-old female with cystic fibrosis. The infection was identified using a Bruker MALDI-TOF Biotyper with BDAL (v12) of blood, which was cultured due to pyrexia and rigour following port-a-cath access. This report details the effective eradication of
C. shandongense
infection from the port-a-cath device using initial empirical gentamicin followed by targeted ciprofloxacin locks and systemic antibiotics.
Conclusion. We demonstrated successful eradication of
C. shandongense
from a port-a-cath device, including the minimum inhibitory concentrations (MICs) required in this case. The result was eradication of central access infection, preventing progression to bacteraemia/septicaemia and preserving central access in a child with cystic fibrosis and established respiratory disease.